Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELDN Eledon Pharmaceuticals	$3.38 +7.3%	$3.16	$2.38 ▼ $5.54	$188.63M	-0.15	675,391 shs	648,913 shs
IFRX InflaRx	$0.86 -5.0%	$0.88	$0.71 ▼ $2.82	$60.76M	1.29	368,745 shs	123,610 shs
PRQR ProQR Therapeutics	$2.08 -1.0%	$2.05	$1.07 ▼ $4.62	$220.95M	0.43	209,588 shs	139,878 shs
RAPT Rapt Therapeutics	$10.49 -2.9%	$9.23	$5.67 ▼ $26.56	$178.59M	0.01	98,493 shs	31,794 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELDN Eledon Pharmaceuticals	+7.30%	-6.63%	+10.46%	+2.11%	+14.97%
IFRX InflaRx	-4.97%	-4.31%	+6.04%	-50.29%	-42.67%
PRQR ProQR Therapeutics	-0.95%	-6.73%	-2.35%	+4.52%	+7.77%
RAPT Rapt Therapeutics	-2.87%	-21.19%	+30.96%	+35.63%	-58.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELDN Eledon Pharmaceuticals	2.1745 of 5 stars	3.5	2.0	0.0	2.9	1.7	0.0
IFRX InflaRx	3.1968 of 5 stars	3.5	5.0	0.0	2.3	1.7	0.6
PRQR ProQR Therapeutics	2.1432 of 5 stars	3.6	3.0	0.0	3.2	0.0	0.0
RAPT Rapt Therapeutics	4.0217 of 5 stars	3.3	1.0	4.2	3.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELDN Eledon Pharmaceuticals	3.00	Buy	$10.00	195.86% Upside
IFRX InflaRx	3.00	Buy	$6.60	667.44% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	284.62% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$20.57	96.11% Upside

Current Analyst Ratings Breakdown

Latest IFRX, RAPT, PRQR, and ELDN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/25/2025	ELDN Eledon Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/18/2025	ELDN Eledon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.98 per share	N/A
IFRX InflaRx	$180K	320.73	N/A	N/A	$1.13 per share	0.76
PRQR ProQR Therapeutics	$20.46M	10.70	N/A	N/A	$0.91 per share	2.29
RAPT Rapt Therapeutics	$1.53M	113.40	N/A	N/A	$11.51 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELDN Eledon Pharmaceuticals	-$36.18M	-$2.10	N/A	N/A	N/A	N/A	-79.54%	-41.62%	8/18/2025 (Estimated)
IFRX InflaRx	-$49.85M	-$0.82	N/A	N/A	N/A	N/A	-64.17%	-53.39%	8/7/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)

Latest IFRX, RAPT, PRQR, and ELDN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	ELDN Eledon Pharmaceuticals	-$0.23	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	IFRX InflaRx	-$0.24	N/A	N/A	N/A	$0.02 million	N/A
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A
5/7/2025	Q1 2025	IFRX InflaRx	-$0.18	-$0.14	+$0.04	-$0.14	$0.03 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELDN Eledon Pharmaceuticals	N/A	13.90	13.91
IFRX InflaRx	N/A	5.28	4.86
PRQR ProQR Therapeutics	N/A	4.10	4.10
RAPT Rapt Therapeutics	N/A	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELDN Eledon Pharmaceuticals	56.77%
IFRX InflaRx	42.39%
PRQR ProQR Therapeutics	32.65%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
ELDN Eledon Pharmaceuticals	12.30%
IFRX InflaRx	16.30%
PRQR ProQR Therapeutics	8.40%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.52 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

IFRX, RAPT, PRQR, and ELDN Headlines

Recent News About These Companies

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1 at 10:56 AM | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded to Neutral at JPMorgan Chase & Co.

August 1 at 2:16 AM | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" Rating

July 31 at 7:33 AM | marketbeat.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30 at 11:42 PM | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30 at 11:42 PM | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30 at 11:42 PM | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street Zen

July 28, 2025 | americanbankingnews.com

What is Lifesci Capital's Estimate for RAPT Q2 Earnings?

July 27, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

July 26, 2025 | marketbeat.com

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

July 25, 2025 | marketbeat.com

Lifesci Capital Upgrades Rapt Therapeutics (NASDAQ:RAPT) to Strong-Buy

July 25, 2025 | americanbankingnews.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci Capital

July 23, 2025 | marketbeat.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Brokerages

July 23, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from Analysts

July 23, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | msn.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | zacks.com

Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board

July 15, 2025 | tmcnet.com

Best Momentum Stocks to Buy for July 15th

July 15, 2025 | zacks.com

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

July 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, RAPT, PRQR, and ELDN Company Descriptions

Eledon Pharmaceuticals NASDAQ:ELDN

$3.38 +0.23 (+7.30%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.53 +0.15 (+4.44%)

As of 08/1/2025 07:59 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

InflaRx NASDAQ:IFRX

$0.86 -0.05 (-4.97%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.86 +0.00 (+0.12%)

As of 08/1/2025 04:15 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

ProQR Therapeutics NASDAQ:PRQR

$2.08 -0.02 (-0.95%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.00 (+0.19%)

As of 08/1/2025 04:11 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Rapt Therapeutics NASDAQ:RAPT

$10.49 -0.31 (-2.87%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.52 +0.03 (+0.24%)

As of 08/1/2025 07:04 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time